Five monumental Alzheimer’s discoveries scientists made in 2024

With an estimated 6.9 million Americans aged 65 and older currently living with Alzheimer’s disease, the road to a cure seems long and uncertain.

But as the year comes to a close, experts are reflecting on some of the hopeful advances in diagnosis, treatment and risk management that have been made in 2024.

The Alzheimer’s Association — a Chicago-based nonprofit committed to Alzheimer’s research, care and support — shared its top five significant discoveries from the year.

1. Third new Alzheimer’s drug is approved

2024 saw a new drug enter the dementia landscape, as the U.S. Food and Drug Administration (FDA) approved Kisunla (donanemab) in July.

This was the third new approval since 2021.

Kisunla, which is made by Eli Lilly, is designed to “slow progression and change the underlying course of the disease,” according to the Association’s press release.

The once-monthly injection is intended for adults with early symptomatic Alzheimer’s disease.

This is the first medication to target amyloid plaques — the proteins that build up in the brains of Alzheimer’s patients, often impairing memory and cognitive function — with evidence to support stopping therapy when amyloid plaques are removed, a company release stated.

“This is real progress,” said Alzheimer’s Association President and CEO Dr. Joanne Pike in a statement shared with Fox News Digital at the time. 

“[This FDA] approval allows people more options and greater opportunity to have more time. Having multiple treatment options is the kind of advancement we’ve all been waiting for.” 

In July, the U.S. Food and Drug Administration (FDA) approved the drug Kisunla to slow down the disease’s progression. Creativa Images – stock.adobe.com

2. Blood tests could improve speed and accuracy of diagnosis

Research this year has helped move Alzheimer’s blood tests closer to being used in physicians’ offices.

Studies have shown that blood tests can achieve a higher accuracy of diagnosis, which could help fast-track patients’ access to clinical trials and treatments, according to the Alzheimer’s Association.

“Blood tests for Alzheimer’s are demonstrating in research that they could significantly improve a clinician’s accuracy and confidence, provide greater accessibility and a reason for more communication,” the same source stated.

In one study reported this year, a specific blood test was around 90% accurate in identifying Alzheimer’s in patients with cognitive symptoms seen in primary care and at specialized memory care clinics, per the Association.

Alzheimer’s Association President and CEO Dr. Joanne Pike said “This is real progress,” when it came to approving the drug being used on patients riddled with the disease. The Washington Post via Getty Images

3. Individuals and caregivers want more support post-diagnosis

People who are newly diagnosed with Alzheimer’s and their caregivers need more support in navigating the health care system.

That’s according to a 2024 Alzheimer’s Association survey, which found that 97% of dementia caregivers expressed a desire for those support systems. 

A majority of dementia caregivers (70%) also noted that “coordination of care is stressful.”

To help address this, the Centers for Medicare & Medicaid Services in July 2024 launched an eight-year pilot program in dementia care management, called the Guiding an Improved Dementia Experience (GUIDE) model.

The program aims to work with health care systems to provide supportive services to people living with dementia and their caregivers, with a focus on helping patients remain in their homes and communities, according to the Alzheimer’s Association.

4. Wildfire smoke raises risk of dementia

Air pollution has been linked to an increased risk of dementia, according to 2024 research. 

The 10-year study, which was presented during the Alzheimer’s Association International Conference in Philadelphia in July, found that wildfire smoke can be “particularly hazardous” for brain health.

The research included more than 1.2 million people in southern California, an area that experiences frequent wildfire activity.

Air pollution produced by wildfires could be more hazardous to health because it is produced at higher temperatures, contains a greater concentration of toxic chemicals, and is smaller in diameter than other sources, the Alzheimer’s Association stated. 

5. Alzheimer’s causes physical changes in the brain

In June 2024, scientists and clinicians published research that showed physical changes that happen in the brain due to Alzheimer’s disease.

“Defining diseases by the biology has long been standard in many areas of medicine — including cancer, heart disease and diabetes,” the Alzheimer’s Association wrote. 

“The new publication defines Alzheimer’s as a biological process that begins with brain changes before people exhibit memory and thinking problems.”

These brain changes were found to come ahead of the typical outward symptoms, such as memory loss, confusion, disorientation and trouble with planning or organizing.

Additional research and support resources from the Alzheimer’s Association can be found at www.alz.org.